Cite
HARVARD Citation
Zhou, Y. et al. (2020). A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab. Lung cancer. pp. 55-59. [Online].